Form 8-K - Current report:
SEC Accession No. 0001193125-25-140739
Filing Date
2025-06-13
Accepted
2025-06-13 16:07:57
Documents
14
Period of Report
2025-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d948514d8k.htm   iXBRL 8-K 48215
2 EX-10.1 d948514dex101.htm EX-10.1 83937
3 EX-10.2 d948514dex102.htm EX-10.2 42773
  Complete submission text file 0001193125-25-140739.txt   326620

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250611.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250611_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250611_pre.xml EX-101.PRE 11252
16 EXTRACTED XBRL INSTANCE DOCUMENT d948514d8k_htm.xml XML 3653
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 251046573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)